Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
about
Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemiaCancer pharmacogenomics, challenges in implementation, and patient-focused perspectivesALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsMechanisms of drug resistance in kinases.miRNAs as Biomarkers in Chronic Myelogenous LeukemiaDynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro dataEffects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cellsA novel quantitative kinase assay using bacterial surface display and flow cytometryThe conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRαActivation state-selective kinase inhibitor assay based on ion mobility-mass spectrometryABCB1 genetic variants in leukemias: current insights into treatment outcomesMolecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemiaAnti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia modelChronic Myeloid Leukemia in India.Guide to interpreting disease responses in chronic myeloid leukemia.Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.Advances in haematological pharmacotherapy in 21st century.Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cellsGalectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemiaOutcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureIn-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia.Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar.Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies.Management of imatinib-resistant patients with chronic myeloid leukemia.Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cellsImpact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinibEmerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.Chronic myeloid leukemia stem cells and developing therapies.AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Treatment options for chronic myeloid leukemia.Tyrosine kinase inhibitors in acute and chronic leukemias.Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.
P2860
Q24622397-9598BEE6-8815-4EFB-BCF5-A6E3847A3B82Q26741009-FF78B1DF-75EC-4C19-A6D2-32C5284D35A4Q26820845-40E1B74D-AAA0-47A1-B81E-F5B2DB941816Q27692567-2777864B-34C3-45F3-9764-8E3AD883D7DAQ28087081-32290329-09C7-4EA9-8D37-83B7DE2C917AQ28478542-7522A60A-8E48-4C57-9CEE-BE8C58756188Q28485087-1DF669E8-3FDE-4912-96D5-6AB2DA21BDD9Q28535179-8567F1EA-9D15-4C09-BCAA-9DE3372137B7Q28535951-F17DBE73-DEFD-42C2-9FEE-B774D738B277Q30352015-B1371331-9C0D-46A6-9C43-FFCE4CCE356EQ33707782-E271769D-9E77-4EB3-9E90-A09534BD2D5CQ33770326-363D246B-C380-4EDE-AC2D-A3A352B71733Q33781191-5732D99B-CD7C-4C6F-80B1-949E1503F6E2Q33815423-7C8460D1-BD00-4024-AE82-1F66E3DC56EFQ33859551-A0952368-399F-4301-832C-EB0E825A89EBQ33885637-B957F037-112D-4B07-9CE0-677D247C8731Q34004994-00B7BC68-999A-4FC9-9879-B7A7C00FD475Q34406838-A87B8CC2-7CE6-43AC-A699-96F4AA813706Q34417824-4D36516F-8A56-4C3B-B47D-D5736FC4365AQ34525925-DAAA0C6C-0AD3-4527-BFBB-D417A7423C21Q34774289-6842944B-3AFD-48EC-A67E-109423357118Q35048118-94E548DA-5B1C-4514-B450-3113D2F0B184Q35409569-2B0B4AC6-25CD-49CB-B231-8C54793F4834Q35596200-8F5AB762-B97F-481E-86F4-81149461193BQ35812209-6B44D88D-5986-4560-9697-CCB3BB790BC5Q36106108-40081DBF-4888-4BB4-A9BB-FDD69B20A38CQ36331689-F6D12D92-14CD-4821-B571-E9B2166419D2Q36525865-99A6E0F5-F86C-455F-AFD5-BB1BA6DBF7EAQ36699009-33ECE954-46FD-4BB7-8629-B9D8AE49181FQ36776423-31D4260A-22E6-471D-9600-61115C5B03A0Q37051682-4B8945DA-D581-4672-A478-397D98B3C2ECQ37087238-AAABF96B-8EA4-4240-8937-69FEDB44F206Q37249366-888530E2-00A8-4C4A-A0A8-078EFED1EE12Q37836936-01EC0CED-7A31-425F-BD3C-5F24DB025715Q37976243-16CE3A96-5468-4829-A037-35FDFB668FB4Q37988569-BD33F93B-7D58-4172-82FA-C5488FD04AC7Q37994805-D096DE7F-A8C9-42F3-A648-73B914AB5105Q38004075-AAF201B3-2CC6-4CBD-BD92-1C7301D706B6Q38133575-92985EA3-9043-40BC-BE97-66D842CF0CEEQ38187115-FDA0C450-A1F3-4EF3-B586-F48AA40A2E51
P2860
Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanisms of resistance to ty ...... tegies to overcome resistance.
@en
Mechanisms of resistance to ty ...... tegies to overcome resistance.
@nl
type
label
Mechanisms of resistance to ty ...... tegies to overcome resistance.
@en
Mechanisms of resistance to ty ...... tegies to overcome resistance.
@nl
prefLabel
Mechanisms of resistance to ty ...... tegies to overcome resistance.
@en
Mechanisms of resistance to ty ...... tegies to overcome resistance.
@nl
P1476
Mechanisms of resistance to ty ...... tegies to overcome resistance.
@en
P2093
Dale Bixby
Moshe Talpaz
P304
P356
10.1182/ASHEDUCATION-2009.1.461
P577
2009-01-01T00:00:00Z